



Press Release

Eurocor presented 12 months outcomes of Spanish Registry on the occasion of EuroPCR in Paris

- **During the Symposium (Drug-eluting balloons: current practice and future perspectives) sponsored with an unrestricted Grant from Eurocor, the 12 month FU results of the Spanish multicenter registry were presented by the Principal Investigator Dr. Antonio Serra**
- **International Symposium dedicated to experiences with drug-eluting balloons (DEB)**

Paris, May 18, 2011 – On the occasion of EuroPCR Dr. Antonio Serra (Spain) announced the 12 months outcomes of the Spanish multicenter registry in Paris during the international Eurocor Symposium on March 17, 2011. The study was conducted to investigate the outcome after DIOR® drug-eluting balloon (DEB) treatment of in-stent restenosis (ISR) lesions. All ISR were investigating bare metal stent ISR as well as drug-eluting stent ISR. A second focus of that study was the treatment of small vessels, a challenging subset of patients where treatment options are currently limited. 250 patients were enrolled in 10 Spanish centers. The results at 12 months follow up show a low target lesion revascularization (TLR) rate of 9.2% in BMS-ISR and 14.8% in DES-ISR. In very small vessels (1.98 mm mean vessel diameter) the TLR rate at 12 months was very low with 2.9%, what is remarkable. This shows that the treatment of coronary in-stent restenosis with the paclitaxel-eluting balloon DIOR® provides good immediate and mid-term outcomes. The manuscript on the subset of patients with ISR lesions has been accepted for publication recently.

During the well visited symposium Prof. Silber (Germany) provided a lecture on the current role of DEBs. He pointed out, that the DIOR DEB is according to the ESC guidelines (2010) IIa, which recommends that DEB can be used for ISR in BMS. Dr. Pieter Stella (Netherlands) then presented the database of the Valentines Trial with the largest group of patients ever enrolled to show efficacy of DEB in treatment of ISR. The



studies show that the DIOR® (DEB) is safe and effective in treatment of in-stent restenosis (ISR).

Prof. Schulte from Germany highlighted a glimpse of first experiences with the drug-eluting peripheral PTA Balloon FREEWAY™ and announced first results of new randomizes studies. Dr. Chandra from India, Dr. Alfredo Rodriguez from Argentina and Prof. Huay Cheem Tan from Singapore rounded the international view on innovative drug-eluting balloon technologies and experiences with high class products such as DIOR® DEB and FREEWAY™ DEB.

-End-

Media Contact

Eurocor GmbH

Claudia Tischendorf

Phone: +49 (0) 228 201 50 26

Email: pressoffice@eurocor.de

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Bonn. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One Heartbeat ahead™ – with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is an Opto Circuits (India) Ltd. Company.

For more information, please visit eurocor.de and optocircuits.com.